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Nausea and vomiting are common symptoms in a patient with cancer. They may be due directly to the tumour itselfor may be side effects oftreatment given, this being aimed at achieving either disease remission or symptom relief. With the advent of new anti-emetic agents, such as the anti 5HT3 class of drugs, treatment for nausea and vomiting can be more specifically targeted to the causal factor. Among factors that can induce nausea and vomiting are liver metastatic deposits. The nausea and vomiting produced by hepatic secondaries can respond to "conventional" anti-emetics but on occasions can be resistant to such treatment and necessitate the use of dexamethasone which can be highly effective but takes 24-48 hours to have the desired effect. Obviously this time delay is unpleasant for the patient and reduces the quality of life when quantity of life is restricted. The following two case reports highlight the potential beneficial effects of intravenous phentolamine in achieving symptom control rapidly and buying time for the more prolonged effects of dexamethasone to become apparent. CASE 1 A 40 year old female was referred with intractable nausea and vomiting unresponsive to metoclopramide, cyclizine and ondansetron. She had an inoperable gastric carcinoma with liver secondaries, and no radiological or endoscopic evidence of obstruction. Her liver was enlarged. An initial intravenous bolus of 10 mg of phentolamine was given which removed nausea within minutes. This was followed by a bolus of 16 mg of dexamethasone intravenously and a reducing course of oral dexamethasone starting at 8 mg/day. This patient had good relief for five days but was unfortunately unable to tolerate the dexamethasone which was stopped after 3 days. At this stage a further 10 mg bolus ofphentolamine was given with good immediate effect and she was commenced on an intravenous infusion of phentolamine (1 5 mg/24 hrs) via a syringe driver (Graseby Ltd). After 24 hours the cannula had to be removed due to phlebitis and was replaced by a 15 cm cannula (Vygon Leaderflex) and the infusion recommenced with good effect. CASE 2 A 77 year old lady was referred with nausea and vomiting associated with a neoplasm involving the head of the pancreas with secondaries in the porta hepatis and liver which were diagnosed at laparotomy. No bowel obstruction was noted. A choledocojejunostomy was performed because ofa distended gall bladder. Treatment with metoclopramide and cyclizine was unsuccessful. On examination she had a tender enlarged liver and was jaundiced. An intravenous injection of 10 mg phentolamine gave relief of nausea in minutes. This treatment was followed by 16 mg intravenously of dexamethasone and an oral reducing course of dexamethasone commencing at 8 mg daily in divided doses over a 9 day period. There was no return of nausea or vomiting in the subsequent 4 weeks until her demise.
DISCUSSION
Phentolamine is a short-acting parenteral alpha blocker which in the past was mainly used in anaesthetic practice as a vasodilator/antihypertensive. More recently it has been used in the diagnosis of sympathetically maintained pain. It has a short half-life but when used to diagnose sympathetically maintained pain its beneficial
The Ulster Medical Journal effect can last for up to 48 hours. The etiology of the nausea and vomiting associated with liver secondaries is not entirely clear but may be related to stretching of the sympathetically innervated liver capsule (via the hepatic plexus, a derivative of the coeliac plexus,2) giving rise not only to nausea and vomiting but also to abdominal pain. Dexamethasone would be expected to have a beneficial effect by reducing peri-tumour oedema and hence stretch on the capsule. On this basis it may be that the blockade of sympathetic nerves around the liver capsule produced by phentolamine is a cause of the reduction in nausea and vomiting associated with this agent. The transient hypotension which accompanies its use (caused by a similar blockade of vascular sympathetic fibres) is rarely troublesome '4 and does not often require intervention. Palpitations may occur but again are short lived. Perhaps the most marked drawback to phentolamine is the need to administer it parentally but despite this it has proved to be a major asset in acute management of the nausea and vomiting associated with liver secondaries and as such merits further investigation.
